3 unknown, 3 withdrawn, 1 completed, 1 suspended. 6 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Withdrawn 3, Completed 1, Suspended 1, Unknown 1 |
| Phase 3 | 3 | Unknown 2, Withdrawn 1 |
Follow Shi Ming: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T Candonilimab, Bevacizumab - Hepatocellular Carcinoma | Phase 2 | Unknown | Shi Ming | 30 | 2023-02-27 | 2023-03-08 |
| Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T Candonilimab, Bevacizumab - Hepatocellular Carcinoma | Phase 2 | Withdrawn | Shi Ming | 2022-12-07 | 2023-06-02 | |
| HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC oxaliplatin , fluorouracil, and leucovorin, gemcitabine and cisplatin - Intrahepatic Cholangiocarcinoma | Phase 3 | Unknown | Shi Ming | 188 | 2021-07-09 | 2021-07-14 |
| Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection Lenvatinib, Nivolumab - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Withdrawn | Shi Ming | 2019-10-30 | 2020-01-09 | |
| HAIC Plus Lenvatinib and Toripalimab for Advanced HCC Hepatic arterial infusion chemotherapy, Lenvatinib, Toripalimab - Hepatocellular Carcinoma | Phase 2 | Completed | Shi Ming | 36 | 2019-08-01 | 2023-06-12 |
| Lenvatinib Plus PD-1 Antibody for Unresectable ICC Lenvatinib, PD-1 antibody - Intrahepatic Cholangiocarcinoma | Phase 2 | Suspended | Shi Ming | 25 | 2018-12-17 | 2019-01-28 |
| Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria Lenvatinib, PD-1 antibody - Hepatocellular Carcinoma | Phase 2 | Withdrawn | Shi Ming | 2018-12-01 | 2019-05-06 | |
| HAIC Versus Systemic Chemotherapy for Unresectable ICC irinotecan, oxaliplatin , fluorouracil, and leucovorin, gemcitabine and oxaliplatin - Intrahepatic Cholangiocarcinoma | Phase 3 | Unknown | Shi Ming | 188 | 2018-08-01 | 2019-12-05 |
Carcinoma, Hepatocellular (5) · Cholangiocarcinoma (3) · Hepatitis B (1)
lenvatinib (4) · Bevacizumab (2) · Fluorouracil (2) · Gemcitabine (2) · Leucovorin (2) · Oxaliplatin (2) · spartalizumab (2) · Cisplatin (1) · Irinotecan (1) · Nivolumab (1) · toripalimab (1)
China (8)
Ming Shi, MD (2)